...
机译:拉帕替尼联合卡培他滨或拉帕替尼联合拓扑替康治疗HER2阳性乳腺癌脑转移患者的II期随机研究
Division of Women’s Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA;
Frauen Klinik Vom Roten Kreuz, Munich, Germany;
IIIrd Medical Department with Hematology and Medical Oncology, Private Medical University Hospital, Salzburg, Austria;
Centre Rene Gauducheau, Saint-Herblain, France;
Sheba Medical Center, Tel Hasomer, Israel;
GlaxoSmithKline, Collegeville, PA, USA;
GlaxoSmithKline, Collegeville, PA, USA;
GlaxoSmithKline, Collegeville, PA, USA;
GlaxoSmithKline, Collegeville, PA, USA;
Division of Women’s Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA;
Lapatinib; Capecitabine; Topotecan; Brain metastases; Breast cancer;
机译:拉帕替尼联合卡培他滨或拉帕替尼联合拓扑替康治疗HER2阳性乳腺癌脑转移患者的II期随机研究。
机译:拉帕替尼和卡培他滨全口服联合治疗HER2阳性乳腺癌脑转移患者的II期研究
机译:拉帕替尼联合卡培他滨治疗HER2阳性转移性乳腺癌(LANDSCAPE)先前未经治疗的脑转移患者:单组2期研究
机译:皮肤癌转移的最小毒性方法:卡培他滨增强的光动力疗法
机译:拉帕替尼和类维生素A在克服乳腺癌激素治疗的内在抗性中的作用
机译:BMET-20RTOG1119 II期随机分组研究同时患有拉帕替尼的全脑放疗在患有Her2阳性乳腺癌的脑转移患者中的应用:NRG和Krog的协作研究(NCT01622868)
机译:拉帕替尼和卡培他滨在HER2阳性乳腺癌脑转移患者中的全口服组合 - 一项II期研究